{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T21:54:55Z","timestamp":1794002095563,"version":"4.8.0"},"reference-count":155,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T00:00:00Z","timestamp":1744675200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T00:00:00Z","timestamp":1744675200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Urol"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1038\/s41585-025-01023-9","type":"journal-article","created":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T11:05:02Z","timestamp":1744715102000},"page":"590-608","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":44,"title":["Circulating tumour DNA and circulating tumour cells in bladder cancer \u2014 from discovery to clinical implementation"],"prefix":"10.1038","volume":"22","author":[{"given":"Sia V.","family":"Lindskrog","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trine","family":"Strandgaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iver","family":"Nordentoft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7655-9378","authenticated-orcid":false,"given":"Matthew D.","family":"Galsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Powles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3923-6136","authenticated-orcid":false,"given":"Mads","family":"Agerb\u00e6k","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f8rgen Bjerggaard","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6401-2903","authenticated-orcid":false,"given":"Catherine","family":"Alix-Panabi\u00e8res","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7061-9851","authenticated-orcid":false,"given":"Lars","family":"Dyrskj\u00f8t","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,15]]},"reference":[{"key":"1023_CR1","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1038\/s41572-023-00468-9","volume":"9","author":"L Dyrskj\u00f8t","year":"2023","unstructured":"Dyrskj\u00f8t, L. et al. Bladder cancer. Nat. Rev. Dis. Primers\u00a09, 58 (2023).","journal-title":"Nat. Rev. Dis. Primers"},{"key":"1023_CR2","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1158\/2159-8290.CD-20-1311","volume":"11","author":"C Alix-Panabi\u00e8res","year":"2021","unstructured":"Alix-Panabi\u00e8res, C. & Pantel, K. Liquid biopsy: from discovery to clinical application. Cancer Discov. 11, 858\u2013873 (2021).","journal-title":"Cancer Discov."},{"key":"1023_CR3","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1038\/s41585-023-00773-8","volume":"20","author":"M Maas","year":"2023","unstructured":"Maas, M., Todenh\u00f6fer, T. & Black, P. C. Urine biomarkers in bladder cancer\u00a0\u2014 current status and future perspectives. Nat. Rev. Urol. 20, 597\u2013614 (2023).","journal-title":"Nat. Rev. Urol."},{"key":"1023_CR4","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/nrc.2017.7","volume":"17","author":"JCM Wan","year":"2017","unstructured":"Wan, J. C. M. et al. Liquid biopsies come of age: towards implementation of circulating tumour DNA. Nat. Rev. Cancer 17, 223\u2013238 (2017).","journal-title":"Nat. Rev. Cancer"},{"key":"1023_CR5","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/s41585-020-0304-1","volume":"17","author":"JJ Meeks","year":"2020","unstructured":"Meeks, J. J. et al. Genomic heterogeneity in bladder cancer: challenges and possible solutions to improve outcomes. Nat. Rev. Urol. 17, 259\u2013270 (2020).","journal-title":"Nat. Rev. Urol."},{"key":"1023_CR6","doi-asserted-by":"publisher","first-page":"103166","DOI":"10.1016\/j.critrevonc.2020.103166","volume":"157","author":"Z Hu","year":"2021","unstructured":"Hu, Z., Chen, H., Long, Y., Li, P. & Gu, Y. The main sources of circulating cell-free DNA: apoptosis, necrosis and active secretion. Crit. Rev. Oncol. Hematol. 157, 103166 (2021).","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"1023_CR7","doi-asserted-by":"publisher","first-page":"E5503","DOI":"10.1073\/pnas.1508736112","volume":"112","author":"K Sun","year":"2015","unstructured":"Sun, K. et al. Plasma DNA tissue mapping by genome-wide methylation sequencing for noninvasive prenatal, cancer, and transplantation assessments. Proc. Natl Acad. Sci. USA 112, E5503\u2013E5512 (2015).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1023_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-07466-6","volume":"9","author":"J Moss","year":"2018","unstructured":"Moss, J. et al. Comprehensive human cell-type methylation atlas reveals origins of circulating cell-free DNA in health and disease. Nat. Commun. 9, 5068 (2018).","journal-title":"Nat. Commun."},{"key":"1023_CR9","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1038\/s41586-019-1272-6","volume":"570","author":"S Cristiano","year":"2019","unstructured":"Cristiano, S. et al. Genome-wide cell-free DNA fragmentation in patients with cancer. Nature 570, 385\u2013389 (2019).","journal-title":"Nature"},{"key":"1023_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-69432-x","volume":"10","author":"M Alcaide","year":"2020","unstructured":"Alcaide, M. et al. Evaluating the quantity, quality and size distribution of cell-free DNA by multiplex droplet digital PCR. Sci. Rep. 10, 12564 (2020).","journal-title":"Sci. Rep."},{"key":"1023_CR11","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1080\/15384047.2019.1598759","volume":"20","author":"A Kustanovich","year":"2019","unstructured":"Kustanovich, A., Schwartz, R., Peretz, T. & Grinshpun, A. Life and death of circulating cell-free DNA. Cancer Biol. Ther. 20, 1057\u20131067 (2019).","journal-title":"Cancer Biol. Ther."},{"key":"1023_CR12","first-page":"646","volume":"37","author":"SA Leon","year":"1977","unstructured":"Leon, S. A., Shapiro, B., Sklaroff, D. M. & Yaros, M. J. Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res. 37, 646\u2013650 (1977).","journal-title":"Cancer Res."},{"key":"1023_CR13","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/nrclinonc.2017.14","volume":"14","author":"G Siravegna","year":"2017","unstructured":"Siravegna, G., Marsoni, S., Siena, S. & Bardelli, A. Integrating liquid biopsies into the management of cancer. Nat. Rev. Clin. Oncol. 14, 531\u2013548 (2017).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1023_CR14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1006162","volume":"12","author":"HR Underhill","year":"2016","unstructured":"Underhill, H. R. et al. Fragment length of circulating tumor DNA. PLoS Genet. 12, e1006162 (2016).","journal-title":"PLoS Genet."},{"key":"1023_CR15","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aat4921","volume":"10","author":"F Mouliere","year":"2018","unstructured":"Mouliere, F. et al. Enhanced detection of circulating tumor DNA by fragment size analysis. Sci. Transl. Med. 10, eaat4921 (2018).","journal-title":"Sci. Transl. Med."},{"key":"1023_CR16","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1158\/2159-8290.CD-19-0622","volume":"10","author":"P Jiang","year":"2020","unstructured":"Jiang, P. et al. Plasma DNA end-motif profiling as a fragmentomic marker in cancer, pregnancy, and transplantation. Cancer Discov. 10, 664\u2013673 (2020).","journal-title":"Cancer Discov."},{"key":"1023_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-05606-z","volume":"12","author":"H Markus","year":"2022","unstructured":"Markus, H. et al. Refined characterization of circulating tumor DNA through biological feature integration. Sci. Rep. 12, 1928 (2022).","journal-title":"Sci. Rep."},{"key":"1023_CR18","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.tig.2023.01.004","volume":"39","author":"T Moser","year":"2023","unstructured":"Moser, T., K\u00fchberger, S., Lazzeri, I., Vlachos, G. & Heitzer, E. Bridging biological cfDNA features and machine learning approaches. Trends Genet. 39, 285\u2013307 (2023).","journal-title":"Trends Genet."},{"key":"1023_CR19","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1016\/j.annonc.2022.05.520","volume":"33","author":"J Pascual","year":"2022","unstructured":"Pascual, J. et al. ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group. Ann. Oncol. 33, 750\u2013768 (2022).","journal-title":"Ann. Oncol."},{"key":"1023_CR20","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1002\/ijc.1434","volume":"94","author":"R von Knobloch","year":"2001","unstructured":"von Knobloch, R. et al. Serum DNA and urine DNA alterations of urinary transitional cell bladder carcinoma detected by fluorescent microsatellite analysis. Int. J. Cancer 94, 67\u201372 (2001).","journal-title":"Int. J. Cancer"},{"key":"1023_CR21","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1158\/1078-0432.CCR-0851-3","volume":"10","author":"R von Knobloch","year":"2004","unstructured":"von Knobloch, R., Brandt, H., Schrader, A. J., Heidenreich, A. & Hofmann, R. Molecular serological detection of DNA alterations in transitional cell carcinoma is highly sensitive and stage independent. Clin. Cancer Res. 10, 988\u2013993 (2004).","journal-title":"Clin. Cancer Res."},{"key":"1023_CR22","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1111\/j.1749-6632.2001.tb03861.x","volume":"945","author":"M Utting","year":"2001","unstructured":"Utting, M., Werner, W., M\u00fcller, G., Schubert, J. & Junker, K. A possible noninvasive method for the detection of bladder cancer in patients: microsatellite analysis of free DNA in urine and blood. Ann. NY Acad. Sci. 945, 31\u201335 (2001).","journal-title":"Ann. NY Acad. Sci."},{"key":"1023_CR23","first-page":"35","volume":"8","author":"M Utting","year":"2002","unstructured":"Utting, M., Werner, W., Dahse, R., Schubert, J. & Junker, K. Microsatellite analysis of free tumor DNA in urine, serum, and plasma of patients: a minimally invasive method for the detection of bladder cancer. Clin. Cancer Res. 8, 35\u201340 (2002).","journal-title":"Clin. Cancer Res."},{"key":"1023_CR24","first-page":"980","volume":"8","author":"G Dom\u00ednguez","year":"2002","unstructured":"Dom\u00ednguez, G. et al. p14ARF promoter hypermethylation in plasma DNA as an indicator of disease recurrence in bladder cancer patients. Clin. Cancer Res. 8, 980\u2013985 (2002).","journal-title":"Clin. Cancer Res."},{"key":"1023_CR25","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/j.juro.2007.08.091","volume":"179","author":"J Ellinger","year":"2008","unstructured":"Ellinger, J. et al. Hypermethylation of cell-free serum DNA indicates worse outcome in patients with bladder cancer. J. Urol. 179, 346\u2013352 (2008).","journal-title":"J. Urol."},{"key":"1023_CR26","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.eururo.2016.01.007","volume":"70","author":"K Birkenkamp-Demtr\u00f6der","year":"2016","unstructured":"Birkenkamp-Demtr\u00f6der, K. et al. Genomic alterations in liquid biopsies from patients with bladder cancer. Eur. Urol. 70, 75\u201382 (2016).","journal-title":"Eur. Urol."},{"key":"1023_CR27","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1016\/j.eururo.2016.12.016","volume":"71","author":"E Christensen","year":"2017","unstructured":"Christensen, E. et al. Liquid biopsy analysis of FGFR3 and PIK3CA hotspot mutations for disease surveillance in bladder cancer. Eur. Urol. 71, 961\u2013969 (2017).","journal-title":"Eur. Urol."},{"key":"1023_CR28","doi-asserted-by":"publisher","first-page":"657483","DOI":"10.3389\/fonc.2021.657483","volume":"11","author":"J Zhang","year":"2021","unstructured":"Zhang, J. et al. Circulating tumor DNA analyses predict disease recurrence in non-muscle-invasive bladder cancer. Front. Oncol. 11, 657483 (2021).","journal-title":"Front. Oncol."},{"key":"1023_CR29","doi-asserted-by":"publisher","first-page":"200818","DOI":"10.1016\/j.omton.2024.200818","volume":"32","author":"M-A Papadimitriou","year":"2024","unstructured":"Papadimitriou, M.-A. et al. CDKN2A copy number alteration in bladder cancer: integrative analysis in patient-derived xenografts and cancer patients. Mol. Ther. Oncol. 32, 200818 (2024).","journal-title":"Mol. Ther. Oncol."},{"key":"1023_CR30","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1200\/JCO.18.02052","volume":"37","author":"E Christensen","year":"2019","unstructured":"Christensen, E. et al. Early detection of metastatic relapse and monitoring of therapeutic efficacy by ultra-deep sequencing of plasma cell-free DNA in patients with urothelial bladder carcinoma. J. Clin. Oncol. 37, 1547\u20131557 (2019).","journal-title":"J. Clin. Oncol."},{"key":"1023_CR31","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1038\/nature22364","volume":"545","author":"C Abbosh","year":"2017","unstructured":"Abbosh, C. et al. Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. Nature 545, 446\u2013451 (2017).","journal-title":"Nature"},{"key":"1023_CR32","doi-asserted-by":"publisher","first-page":"4797","DOI":"10.1158\/1078-0432.CCR-23-1860","volume":"29","author":"SV Lindskrog","year":"2023","unstructured":"Lindskrog, S. V. et al. Circulating tumor DNA analysis in advanced urothelial carcinoma: insights from biological analysis and extended clinical follow-up. Clin. Cancer Res. 29, 4797\u20134807 (2023).","journal-title":"Clin. Cancer Res."},{"key":"1023_CR33","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1016\/j.euo.2024.03.002","volume":"7","author":"R Ben-David","year":"2024","unstructured":"Ben-David, R. et al. Longitudinal tumor-informed circulating tumor DNA status predicts disease upstaging and poor prognosis for patients undergoing radical cystectomy. Eur. Urol. Oncol. 7, 1105\u20131112 (2024).","journal-title":"Eur. Urol. Oncol."},{"key":"1023_CR34","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.euo.2024.07.001","volume":"8","author":"JP Sfakianos","year":"2024","unstructured":"Sfakianos, J. P. et al. Association of tumor-informed circulating tumor DNA detectability before and after radical cystectomy with disease-free survival in patients with bladder cancer. Eur. Urol. Oncol. 8, 306\u2013314 (2024).","journal-title":"Eur. Urol. Oncol."},{"key":"1023_CR35","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1038\/s41586-021-03642-9","volume":"595","author":"T Powles","year":"2021","unstructured":"Powles, T. et al. ctDNA guiding adjuvant immunotherapy in urothelial carcinoma. Nature 595, 432\u2013437 (2021).","journal-title":"Nature"},{"key":"1023_CR36","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.eururo.2023.06.007","volume":"85","author":"T Powles","year":"2024","unstructured":"Powles, T. et al. Updated overall survival by circulating tumor DNA status from the phase 3 IMvigor010 trial: adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma. Eur. Urol. 85, 114\u2013122 (2024).","journal-title":"Eur. Urol."},{"key":"1023_CR37","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.eururo.2022.04.013","volume":"82","author":"B Szabados","year":"2022","unstructured":"Szabados, B. et al. Final results of neoadjuvant atezolizumab in cisplatin-ineligible patients with muscle-invasive urothelial cancer of the bladder. Eur. Urol. 82, 212\u2013222 (2022).","journal-title":"Eur. Urol."},{"key":"1023_CR38","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1038\/s41591-023-02500-7","volume":"30","author":"J van Dorp","year":"2023","unstructured":"van Dorp, J. et al. High- or low-dose preoperative ipilimumab plus nivolumab in stage III urothelial cancer: the phase 1B NABUCCO trial. Nat. Med. 30, 304 (2023).","journal-title":"Nat. Med."},{"key":"1023_CR39","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1038\/s41591-020-0915-3","volume":"26","author":"A Zviran","year":"2020","unstructured":"Zviran, A. et al. Genome-wide cell-free DNA mutational integration enables ultra-sensitive cancer monitoring. Nat. Med. 26, 1114\u20131124 (2020).","journal-title":"Nat. Med."},{"key":"1023_CR40","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1038\/s41591-024-03040-4","volume":"30","author":"AJ Widman","year":"2024","unstructured":"Widman, A. J. et al. Ultrasensitive plasma-based monitoring of tumor burden using machine-learning-guided signal enrichment. Nat. Med. 30, 1655\u20131666 (2024).","journal-title":"Nat. Med."},{"key":"1023_CR41","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.eururo.2024.05.014","volume":"86","author":"I Nordentoft","year":"2024","unstructured":"Nordentoft, I. et al. Whole-genome mutational analysis for tumor-informed detection of circulating tumor DNA in patients with urothelial carcinoma. Eur. Urol. 86, 301\u2013311 (2024).","journal-title":"Eur. Urol."},{"key":"1023_CR42","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1002\/cncr.31314","volume":"124","author":"N Agarwal","year":"2018","unstructured":"Agarwal, N. et al. Characterization of metastatic urothelial carcinoma via comprehensive genomic profiling of circulating tumor DNA. Cancer 124, 2115\u20132124 (2018).","journal-title":"Cancer"},{"key":"1023_CR43","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/j.euo.2019.02.004","volume":"3","author":"P Grivas","year":"2020","unstructured":"Grivas, P. et al. Circulating tumor DNA alterations in advanced urothelial carcinoma and association with clinical outcomes: a pilot study. Eur. Urol. Oncol. 3, 695\u2013699 (2020).","journal-title":"Eur. Urol. Oncol."},{"key":"1023_CR44","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1038\/s41416-021-01648-8","volume":"126","author":"KS Shohdy","year":"2022","unstructured":"Shohdy, K. S. et al. Serial ctDNA analysis predicts clinical progression in patients with advanced urothelial carcinoma. Br. J. Cancer 126, 430\u2013439 (2022).","journal-title":"Br. J. Cancer"},{"key":"1023_CR45","doi-asserted-by":"publisher","first-page":"100004","DOI":"10.1016\/j.esmorw.2023.100004","volume":"3","author":"B Miron","year":"2024","unstructured":"Miron, B. et al. Relationship of tumor fraction in circulating tumor DNA with prognosis in patients with advanced urothelial cancer. ESMO Real. World Data Digital Oncol. 3, 100004 (2024).","journal-title":"ESMO Real. World Data Digital Oncol."},{"key":"1023_CR46","doi-asserted-by":"publisher","first-page":"2458","DOI":"10.1093\/annonc\/mdx405","volume":"28","author":"PC Barata","year":"2017","unstructured":"Barata, P. C. et al. Next-generation sequencing (NGS) of cell-free circulating tumor DNA and tumor tissue in patients with advanced urothelial cancer: a pilot assessment of concordance. Ann. Oncol. 28, 2458\u20132463 (2017).","journal-title":"Ann. Oncol."},{"key":"1023_CR47","doi-asserted-by":"publisher","first-page":"6487","DOI":"10.1158\/1078-0432.CCR-17-1140","volume":"23","author":"G Vandekerkhove","year":"2017","unstructured":"Vandekerkhove, G. et al. Circulating tumor DNA reveals clinically actionable somatic genome of metastatic bladder cancer. Clin. Cancer Res. 23, 6487\u20136497 (2017).","journal-title":"Clin. Cancer Res."},{"key":"1023_CR48","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-20493-6","volume":"12","author":"G Vandekerkhove","year":"2021","unstructured":"Vandekerkhove, G. et al. Plasma ctDNA is a tumor tissue surrogate and enables clinical-genomic stratification of metastatic bladder cancer. Nat. Commun. 12, 184 (2021).","journal-title":"Nat. Commun."},{"key":"1023_CR49","doi-asserted-by":"publisher","first-page":"111859","DOI":"10.1016\/j.celrep.2022.111859","volume":"41","author":"TN Clinton","year":"2022","unstructured":"Clinton, T. N. et al. Genomic heterogeneity as a barrier to precision oncology in urothelial cancer. Cell Rep. 41, 111859 (2022).","journal-title":"Cell Rep."},{"key":"1023_CR50","doi-asserted-by":"publisher","DOI":"10.1200\/PO-24-00472","volume":"9","author":"T Sakatani","year":"2025","unstructured":"Sakatani, T. et al. Clinical utility of serial circulating tumor DNA analysis as a minimally invasive biomarker in advanced urothelial cancer. JCO Precis. Oncol. 9, e2400472 (2025).","journal-title":"JCO Precis. Oncol."},{"key":"1023_CR51","doi-asserted-by":"publisher","first-page":"107550","DOI":"10.1016\/j.celrep.2020.107550","volume":"31","author":"K Litchfield","year":"2020","unstructured":"Litchfield, K. et al. Representative sequencing: unbiased sampling of solid tumor tissue. Cell Rep. 31, 107550 (2020).","journal-title":"Cell Rep."},{"key":"1023_CR52","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-05623-3","volume":"7","author":"KM Patel","year":"2017","unstructured":"Patel, K. M. et al. Association of plasma and urinary mutant DNA with clinical outcomes in muscle invasive bladder cancer. Sci. Rep. 7, 5554 (2017).","journal-title":"Sci. Rep."},{"key":"1023_CR53","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1158\/1078-0432.CCR-22-3250","volume":"29","author":"E Christensen","year":"2023","unstructured":"Christensen, E. et al. Cell-free urine and plasma DNA mutational analysis predicts neoadjuvant chemotherapy response and outcome in patients with muscle-invasive bladder cancer. Clin. Cancer Res. 29, 1582\u20131591 (2023).","journal-title":"Clin. Cancer Res."},{"key":"1023_CR54","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.euo.2023.03.008","volume":"6","author":"Y-T Lu","year":"2023","unstructured":"Lu, Y.-T. et al. Cell-free DNA methylation as a predictive biomarker of response to neoadjuvant chemotherapy for patients with muscle-invasive bladder cancer in SWOG S1314. Eur. Urol. Oncol. 6, 516\u2013524 (2023).","journal-title":"Eur. Urol. Oncol."},{"key":"1023_CR55","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.eururo.2023.08.016","volume":"85","author":"J Alfred Witjes","year":"2023","unstructured":"Alfred Witjes, J. et al. European Association of Urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2023 guidelines. Eur. Urol. 85, 17\u201331 (2023).","journal-title":"Eur. Urol."},{"key":"1023_CR56","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1111\/bju.16556","volume":"135","author":"R Ben-David","year":"2024","unstructured":"Ben-David, R. et al. Undetectable pre-radical cystectomy circulating tumour DNA status predicts improved oncological outcomes. BJU Int. 135, 473\u2013480 (2024).","journal-title":"BJU Int."},{"key":"1023_CR57","doi-asserted-by":"publisher","first-page":"2825","DOI":"10.1038\/s41591-023-02568-1","volume":"29","author":"MD Galsky","year":"2023","unstructured":"Galsky, M. D. et al. Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial. Nat. Med. 29, 2825\u20132834 (2023).","journal-title":"Nat. Med."},{"key":"1023_CR58","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT06537154 (2025)."},{"key":"1023_CR59","doi-asserted-by":"publisher","first-page":"2709","DOI":"10.1038\/s41591-023-02575-2","volume":"29","author":"R Li","year":"2023","unstructured":"Li, R. Organ-sparing precision treatment for muscle-invasive bladder cancer. Nat. Med. 29, 2709\u20132710 (2023).","journal-title":"Nat. Med."},{"key":"1023_CR60","doi-asserted-by":"publisher","DOI":"10.1200\/PO.21.00535","volume":"6","author":"H Bando","year":"2022","unstructured":"Bando, H. et al. Effects of metastatic sites on circulating tumor DNA in patients with metastatic colorectal cancer. JCO Precis. Oncol. 6, e2100535 (2022).","journal-title":"JCO Precis. Oncol."},{"key":"1023_CR61","doi-asserted-by":"publisher","first-page":"6212","DOI":"10.1158\/1078-0432.CCR-18-0386","volume":"24","author":"R Raja","year":"2018","unstructured":"Raja, R. et al. Early reduction in ctDNA predicts survival in patients with lung and bladder cancer treated with durvalumab. Clin. Cancer Res. 24, 6212\u20136222 (2018).","journal-title":"Clin. Cancer Res."},{"key":"1023_CR62","doi-asserted-by":"publisher","first-page":"2086","DOI":"10.1002\/1878-0261.13196","volume":"16","author":"PAJ Mendelaar","year":"2022","unstructured":"Mendelaar, P. A. J. et al. Genome-wide aneuploidy detected by mFast-SeqS in circulating cell-free DNA is associated with poor response to pembrolizumab in patients with advanced urothelial cancer. Mol. Oncol. 16, 2086\u20132097 (2022).","journal-title":"Mol. Oncol."},{"key":"1023_CR63","doi-asserted-by":"publisher","first-page":"389","DOI":"10.3892\/ol.2023.13975","volume":"26","author":"K Hamada","year":"2023","unstructured":"Hamada, K. et al. Variant allele frequency changes in TP53 predict pembrolizumab response in patients with metastatic urothelial carcinoma. Oncol. Lett. 26, 389 (2023).","journal-title":"Oncol. Lett."},{"key":"1023_CR64","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1002\/path.6166","volume":"261","author":"J Zang","year":"2023","unstructured":"Zang, J. et al. Integrated longitudinal circulating tumor DNA profiling predicts immunotherapy response of metastatic urothelial carcinoma in the POLARIS-03 trial. J. Pathol. 261, 198\u2013209 (2023).","journal-title":"J. Pathol."},{"key":"1023_CR65","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.euo.2023.08.009","volume":"7","author":"SH Tolmeijer","year":"2024","unstructured":"Tolmeijer, S. H. et al. Early on-treatment circulating tumor DNA measurements and response to immune checkpoint inhibitors in advanced urothelial cancer. Eur. Urol. Oncol. 7, 282\u2013291 (2024).","journal-title":"Eur. Urol. Oncol."},{"key":"1023_CR66","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.eururo.2019.01.009","volume":"75","author":"N Sundahl","year":"2019","unstructured":"Sundahl, N. et al. Randomized phase 1 trial of pembrolizumab with sequential versus concomitant stereotactic body radiotherapy in metastatic urothelial carcinoma. Eur. Urol. 75, 707\u2013711 (2019).","journal-title":"Eur. Urol."},{"key":"1023_CR67","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1158\/2159-8290.CD-18-0229","volume":"8","author":"SK Pal","year":"2018","unstructured":"Pal, S. K. et al. Efficacy of BGJ398, a fibroblast growth factor receptor 1\u20133 inhibitor, in patients with previously treated advanced urothelial carcinoma with FGFR3 alterations. Cancer Discov. 8, 812\u2013821 (2018).","journal-title":"Cancer Discov."},{"key":"1023_CR68","doi-asserted-by":"publisher","first-page":"113368","DOI":"10.1016\/j.ejca.2023.113368","volume":"195","author":"C Helal","year":"2023","unstructured":"Helal, C. et al. Clinical utility of plasma ctDNA sequencing in metastatic urothelial cancer. Eur. J. Cancer 195, 113368 (2023).","journal-title":"Eur. J. Cancer"},{"key":"1023_CR69","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1158\/1078-0432.CCR-21-2136","volume":"28","author":"JK Lee","year":"2022","unstructured":"Lee, J. K. et al. The pan-tumor landscape of targetable kinase fusions in circulating tumor DNA. Clin. Cancer Res. 28, 728\u2013737 (2022).","journal-title":"Clin. Cancer Res."},{"key":"1023_CR70","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1016\/S1470-2045(20)30445-9","volume":"21","author":"A Marabelle","year":"2020","unstructured":"Marabelle, A. et al. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol. 21, 1353\u20131365 (2020).","journal-title":"Lancet Oncol."},{"key":"1023_CR71","doi-asserted-by":"publisher","first-page":"100003","DOI":"10.1016\/j.jlb.2023.100003","volume":"1","author":"S Mishima","year":"2023","unstructured":"Mishima, S. et al. Validity and utility of blood tumor mutational burden (bTMB) is dependent on circulating tumor DNA (ctDNA) shed: SCRUM-Japan MONSTAR-SCREEN. J. Liq. Biopsy 1, 100003 (2023).","journal-title":"J. Liq. Biopsy"},{"key":"1023_CR72","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1056\/NEJMoa2312117","volume":"390","author":"T Powles","year":"2024","unstructured":"Powles, T. et al. Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer. N. Engl. J. Med. 390, 875\u2013888 (2024).","journal-title":"N. Engl. J. Med."},{"key":"1023_CR73","unstructured":"US Food and Drug Administration. FDA approves enfortumab vedotin-ejfv with pembrolizumab for locally advanced or metastatic urothelial cancer (FDA, 2024)."},{"key":"1023_CR74","doi-asserted-by":"publisher","first-page":"2508","DOI":"10.1038\/s41591-024-03091-7","volume":"30","author":"T Powles","year":"2024","unstructured":"Powles, T. et al. Pembrolizumab for advanced urothelial carcinoma: exploratory ctDNA biomarker analyses of the KEYNOTE-361 phase 3 trial. Nat. Med. 30, 2508\u20132516 (2024).","journal-title":"Nat. Med."},{"key":"1023_CR75","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04138628 (2022)."},{"key":"1023_CR76","doi-asserted-by":"publisher","first-page":"509","DOI":"10.2217\/fon-2022-0868","volume":"19","author":"F Jackson-Spence","year":"2023","unstructured":"Jackson-Spence, F. et al. IMvigor011: a study of adjuvant atezolizumab in patients with high-risk MIBC who are ctDNA+ post-surgery. Future Oncol. 19, 509\u2013515 (2023).","journal-title":"Future Oncol."},{"key":"1023_CR77","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT05987241 (2025)."},{"key":"1023_CR78","doi-asserted-by":"publisher","first-page":"S1133","DOI":"10.1016\/j.annonc.2024.08.2045","volume":"35","author":"J Bjerggaard Jensen","year":"2024","unstructured":"Bjerggaard Jensen, J. et al. 1960O Identification of bladder cancer patients that could benefit from early post-cystectomy immunotherapy based on serial circulating tumour DNA (ctDNA) testing: preliminary results from the TOMBOLA trial. Ann. Oncol. 35, S1133 (2024).","journal-title":"Ann. Oncol."},{"key":"1023_CR79","unstructured":"Powles, T. et al. Clinical outcomes in patients with high-risk, post-cystectomy MIBC with persistent circulating tumour DNA-negative status on serial testing: surveillance analysis from the IMvigor011 study. Presented at the European Association of Urology Annual Meeting (2024)."},{"key":"1023_CR80","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41392-021-00817-8","volume":"6","author":"D Lin","year":"2021","unstructured":"Lin, D. et al. Circulating tumor cells: biology and clinical significance. Signal Transduct. Target. Ther. 6, 1\u201324 (2021).","journal-title":"Signal Transduct. Target. Ther."},{"key":"1023_CR81","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1016\/j.trecan.2021.07.001","volume":"7","author":"E Schuster","year":"2021","unstructured":"Schuster, E. et al. Better together: circulating tumor cell clustering in metastatic cancer. Trends Cancer 7, 1020\u20131032 (2021).","journal-title":"Trends Cancer"},{"key":"1023_CR82","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1016\/j.cell.2014.07.013","volume":"158","author":"N Aceto","year":"2014","unstructured":"Aceto, N. et al. Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis. Cell 158, 1110\u20131122 (2014).","journal-title":"Cell"},{"key":"1023_CR83","doi-asserted-by":"publisher","first-page":"E854","DOI":"10.1073\/pnas.1508541113","volume":"113","author":"KJ Cheung","year":"2016","unstructured":"Cheung, K. J. et al. Polyclonal breast cancer metastases arise from collective dissemination of keratin 14-expressing tumor cell clusters. Proc. Natl Acad. Sci. USA 113, E854\u2013E863 (2016).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1023_CR84","doi-asserted-by":"publisher","first-page":"6897","DOI":"10.1158\/1078-0432.CCR-04-0378","volume":"10","author":"WJ Allard","year":"2004","unstructured":"Allard, W. J. et al. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin. Cancer Res. 10, 6897\u20136904 (2004).","journal-title":"Clin. Cancer Res."},{"key":"1023_CR85","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.cobme.2017.08.001","volume":"3","author":"SH Au","year":"2017","unstructured":"Au, S. H. et al. Clusters of circulating tumor cells: a biophysical and technological perspective. Curr. Opin. Biomed. Eng. 3, 13\u201319 (2017).","journal-title":"Curr. Opin. Biomed. Eng."},{"key":"1023_CR86","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01880-1","volume":"22","author":"NH Stoecklein","year":"2023","unstructured":"Stoecklein, N. H. et al. Ultra-sensitive CTC-based liquid biopsy for pancreatic cancer enabled by large blood volume analysis. Mol. Cancer 22, 181 (2023).","journal-title":"Mol. Cancer"},{"key":"1023_CR87","doi-asserted-by":"publisher","first-page":"E219","DOI":"10.1002\/dc.25141","volume":"51","author":"M Jahan","year":"2023","unstructured":"Jahan, M. et al. Cytomorphologic visualization of circulating tumor cells in urinary bladder cancer patients using ScreenCellTM technology: potential as a simple cytology test. Diagn. Cytopathol. 51, E219\u2013E223 (2023).","journal-title":"Diagn. Cytopathol."},{"key":"1023_CR88","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1111\/j.1442-2042.2010.02454.x","volume":"17","author":"T Okegawa","year":"2010","unstructured":"Okegawa, T., Hayashi, K., Hara, H., Nutahara, K. & Higashihara, E. Immunomagnetic quantification of circulating tumor cells in patients with urothelial cancer. Int. J. Urol. 17, 254\u2013258 (2010).","journal-title":"Int. J. Urol."},{"key":"1023_CR89","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.juro.2014.06.083","volume":"193","author":"H Engilbertsson","year":"2015","unstructured":"Engilbertsson, H. et al. Transurethral bladder tumor resection can cause seeding of cancer cells into the bloodstream. J. Urol. 193, 53\u201357 (2015).","journal-title":"J. Urol."},{"key":"1023_CR90","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jsamd.2019.01.006","volume":"4","author":"P Rostami","year":"2019","unstructured":"Rostami, P. et al. Novel approaches in cancer management with circulating tumor cell clusters. J. Sci. Adv. Mater. Devices 4, 1\u201318 (2019).","journal-title":"J. Sci. Adv. Mater. Devices"},{"key":"1023_CR91","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1002\/1878-0261.12802","volume":"15","author":"PAJ Mendelaar","year":"2021","unstructured":"Mendelaar, P. A. J. et al. Defining the dimensions of circulating tumor cells in a large series of breast, prostate, colon, and bladder cancer patients. Mol. Oncol. 15, 116\u2013125 (2021).","journal-title":"Mol. Oncol."},{"key":"1023_CR92","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1002\/ijc.20366","volume":"111","author":"I Osman","year":"2004","unstructured":"Osman, I. et al. Detection of circulating cancer cells expressing uroplakins and epidermal growth factor receptor in bladder cancer patients. Int. J. Cancer 111, 934\u2013939 (2004).","journal-title":"Int. J. Cancer"},{"key":"1023_CR93","doi-asserted-by":"publisher","first-page":"7217","DOI":"10.1007\/s13277-014-1894-0","volume":"35","author":"F Qi","year":"2014","unstructured":"Qi, F. et al. Quantitation of rare circulating tumor cells by folate receptor \u03b1 ligand-targeted PCR in bladder transitional cell carcinoma and its potential diagnostic significance. Tumour Biol. 35, 7217\u20137223 (2014).","journal-title":"Tumour Biol."},{"key":"1023_CR94","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1080\/14737140.2023.2245144","volume":"23","author":"I Duquesne","year":"2023","unstructured":"Duquesne, I., Chakra, M. A., Hage, L., Pinar, U. & Loriot, Y. Liquid biopsies for detection, surveillance, and prognosis of urothelial cancer: a future standard? Expert Rev. Anticancer Ther. 23, 995\u20131007 (2023).","journal-title":"Expert Rev. Anticancer Ther."},{"key":"1023_CR95","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1002\/cncr.22543","volume":"109","author":"M Naoe","year":"2007","unstructured":"Naoe, M. et al. Detection of circulating urothelial cancer cells in the blood using the CellSearch System. Cancer 109, 1439\u20131445 (2007).","journal-title":"Cancer"},{"key":"1023_CR96","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/j.juro.2015.02.2951","volume":"194","author":"A Alva","year":"2015","unstructured":"Alva, A. et al. Circulating tumor cells as potential biomarkers in bladder cancer. J. Urol. 194, 790\u2013798 (2015).","journal-title":"J. Urol."},{"key":"1023_CR97","doi-asserted-by":"publisher","first-page":"701298","DOI":"10.3389\/fonc.2021.701298","volume":"11","author":"G Fu","year":"2021","unstructured":"Fu, G. et al. Microfluidic assaying of circulating tumor cells and its application in risk stratification of urothelial bladder cancer. Front. Oncol. 11, 701298 (2021).","journal-title":"Front. Oncol."},{"key":"1023_CR98","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1097\/CU9.0000000000000091","volume":"16","author":"M Kobayashi","year":"2022","unstructured":"Kobayashi, M., Abe, H., Arai, K., Murakami, S. & Kamai, T. Circulating tumor cells and cell-free tumor DNA analyses in urothelial cancer using the LiquidBiopsy platform. Curr. Urol. 16, 99\u2013106 (2022).","journal-title":"Curr. Urol."},{"key":"1023_CR99","doi-asserted-by":"publisher","first-page":"606.e9","DOI":"10.1016\/j.urolonc.2017.05.021","volume":"35","author":"J Abrahamsson","year":"2017","unstructured":"Abrahamsson, J. et al. Circulating tumor cells in patients with advanced urothelial carcinoma of the bladder: association with tumor stage, lymph node metastases, FDG-PET findings, and survival. Urol. Oncol. 35, 606.e9\u2013606.e16 (2017).","journal-title":"Urol. Oncol."},{"key":"1023_CR100","doi-asserted-by":"publisher","first-page":"24677","DOI":"10.18632\/oncotarget.8250","volume":"7","author":"K-A Hyun","year":"2016","unstructured":"Hyun, K.-A. et al. Epithelial-to-mesenchymal transition leads to loss of EpCAM and different physical properties in circulating tumor cells from metastatic breast cancer. Oncotarget 7, 24677\u201324687 (2016).","journal-title":"Oncotarget"},{"key":"1023_CR101","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1111\/j.1464-410X.2010.09562.x","volume":"107","author":"M Rink","year":"2011","unstructured":"Rink, M. et al. Detection of circulating tumour cells in peripheral blood of patients with advanced non-metastatic bladder cancer: circulating tumour cells in non-metastatic bladder cancer. BJU Int. 107, 1668\u20131675 (2011).","journal-title":"BJU Int."},{"key":"1023_CR102","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/j.urology.2011.05.045","volume":"78","author":"TW Flaig","year":"2011","unstructured":"Flaig, T. W. et al. Detection of circulating tumor cells in metastatic and clinically localized urothelial carcinoma. Urology 78, 863\u2013867 (2011).","journal-title":"Urology"},{"key":"1023_CR103","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1016\/j.eururo.2012.01.017","volume":"61","author":"M Rink","year":"2012","unstructured":"Rink, M. et al. Prognostic role and HER2 expression of circulating tumor cells in peripheral blood of patients prior to radical cystectomy: a prospective study. Eur. Urol. 61, 810\u2013817 (2012).","journal-title":"Eur. Urol."},{"key":"1023_CR104","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1111\/bju.13782","volume":"119","author":"A Soave","year":"2017","unstructured":"Soave, A. et al. Detection and oncological effect of circulating tumour cells in patients with variant urothelial carcinoma histology treated with radical cystectomy. BJU Int. 119, 854\u2013861 (2017).","journal-title":"BJU Int."},{"key":"1023_CR105","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1002\/ijc.30445","volume":"140","author":"A Soave","year":"2017","unstructured":"Soave, A. et al. A nonrandomized, prospective, clinical study on the impact of circulating tumor cells on outcomes of urothelial carcinoma of the bladder patients treated with radical cystectomy with or without adjuvant chemotherapy: circulating tumor cells and adjuvant chemotherapy after radical cystectomy. Int. J. Cancer 140, 381\u2013389 (2017).","journal-title":"Int. J. Cancer"},{"key":"1023_CR106","doi-asserted-by":"publisher","first-page":"59527","DOI":"10.18632\/oncotarget.18521","volume":"8","author":"Z Zhang","year":"2017","unstructured":"Zhang, Z. et al. The prognostic and diagnostic value of circulating tumor cells in bladder cancer and upper tract urothelial carcinoma: a meta-analysis of 30 published studies. Oncotarget 8, 59527\u201359538 (2017).","journal-title":"Oncotarget"},{"key":"1023_CR107","doi-asserted-by":"publisher","first-page":"e661","DOI":"10.1016\/j.clgc.2017.01.011","volume":"15","author":"GM Busetto","year":"2017","unstructured":"Busetto, G. M. et al. The prognostic role of circulating tumor cells (CTC) in high-risk non-muscle-invasive bladder cancer. Clin. Genitourin. Cancer 15, e661\u2013e666 (2017).","journal-title":"Clin. Genitourin. Cancer"},{"key":"1023_CR108","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1111\/j.1464-410X.2009.09130.x","volume":"106","author":"A Gradilone","year":"2010","unstructured":"Gradilone, A. et al. Prognostic significance of survivin-expressing circulating tumour cells in T1G3 bladder cancer: prognostic significance of survivin-expressing circulating tumour cells in T1G3 bladder cancer. BJU Int. 106, 710\u2013715 (2010).","journal-title":"BJU Int."},{"key":"1023_CR109","doi-asserted-by":"publisher","first-page":"2352","DOI":"10.1093\/annonc\/mdr619","volume":"23","author":"P Gazzaniga","year":"2012","unstructured":"Gazzaniga, P. et al. Prognostic value of circulating tumor cells in nonmuscle invasive bladder cancer: a CellSearch analysis. Ann. Oncol. 23, 2352\u20132356 (2012).","journal-title":"Ann. Oncol."},{"key":"1023_CR110","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.1002\/ijc.28830","volume":"135","author":"P Gazzaniga","year":"2014","unstructured":"Gazzaniga, P. et al. Circulating tumor cells detection has independent prognostic impact in high-risk non-muscle invasive bladder cancer: influence of CTC on the natural course of early bladder cancer. Int. J. Cancer 135, 1978\u20131982 (2014).","journal-title":"Int. J. Cancer"},{"key":"1023_CR111","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.1007\/s00432-017-2449-8","volume":"143","author":"C Nicolazzo","year":"2017","unstructured":"Nicolazzo, C. et al. The long-term prognostic value of survivin expressing circulating tumor cells in patients with high-risk non-muscle invasive bladder cancer (NMIBC). J. Cancer Res. Clin. Oncol. 143, 1971\u20131976 (2017).","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"1023_CR112","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1634\/theoncologist.2018-0784","volume":"24","author":"C Nicolazzo","year":"2019","unstructured":"Nicolazzo, C. et al. Circulating tumor cells identify patients with super-high-risk non-muscle-invasive bladder cancer: updated outcome analysis of a prospective single-center trial. Oncologist 24, 612\u2013616 (2019).","journal-title":"Oncologist"},{"key":"1023_CR113","doi-asserted-by":"publisher","first-page":"2033","DOI":"10.1007\/s00345-022-04061-9","volume":"40","author":"R Carrasco","year":"2022","unstructured":"Carrasco, R. et al. Prognostic implication of TERT promoter mutation and circulating tumor cells in muscle-invasive bladder cancer. World J. Urol. 40, 2033\u20132039 (2022).","journal-title":"World J. Urol."},{"key":"1023_CR114","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/s11255-022-03406-y","volume":"55","author":"J Liu","year":"2023","unstructured":"Liu, J., Ma, C., Li, X., Li, A. & Wang, Z. Circulating tumor cells correlating with Ki-67 predicts the prognosis of bladder cancer patients. Int. Urol. Nephrol. 55, 309\u2013318 (2023).","journal-title":"Int. Urol. Nephrol."},{"key":"1023_CR115","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1111\/iju.12758","volume":"22","author":"B Winters","year":"2015","unstructured":"Winters, B. et al. Chemotherapeutic effects on circulating tumor cells in bladder cancer: CTC in bladder cancer. Int. J. Urol. 22, 612\u2013613 (2015).","journal-title":"Int. J. Urol."},{"key":"1023_CR116","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.3390\/diagnostics13061032","volume":"13","author":"Y-C Jhuo","year":"2023","unstructured":"Jhuo, Y.-C. et al. Circulating tumor cells predict response of neoadjuvant chemotherapy in patients with bladder cancer: a preliminary study. Diagnostics 13, 1032 (2023).","journal-title":"Diagnostics"},{"key":"1023_CR117","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1007\/s13402-023-00785-x","volume":"46","author":"D Jin","year":"2023","unstructured":"Jin, D. et al. In vivo detection demonstrates circulating tumor cell reduction instead of baseline number has prognostic value in bladder cancer patients receiving neoadjuvant chemotherapy. Cell. Oncol. 46, 793\u2013797 (2023).","journal-title":"Cell. Oncol."},{"key":"1023_CR118","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.eururo.2022.09.008","volume":"82","author":"T Strandgaard","year":"2022","unstructured":"Strandgaard, T. et al. Elevated T-cell exhaustion and urinary tumor DNA levels are associated with Bacillus Calmette-Gu\u00e9rin failure in patients with non-muscle-invasive bladder cancer. Eur. Urol. 82, 646\u2013656 (2022).","journal-title":"Eur. Urol."},{"key":"1023_CR119","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1158\/1078-0432.CCR-19-1920","volume":"26","author":"M Kates","year":"2020","unstructured":"Kates, M., Matoso, A., Choi, W., Baras, A. S. & Daniels, M. J. Adaptive immune resistance to intravesical BCG in non-muscle invasive bladder cancer: implications for prospective BCG-unresponsive trials. Clin. Cancer Res. 26, 882\u2013891 (2020).","journal-title":"Clin. Cancer Res."},{"key":"1023_CR120","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abn4118","volume":"15","author":"FC de Jong","year":"2023","unstructured":"de Jong, F. C. et al. Non-muscle-invasive bladder cancer molecular subtypes predict differential response to intravesical Bacillus Calmette-Gu\u00e9rin. Sci. Transl. Med. 15, eabn4118 (2023).","journal-title":"Sci. Transl. Med."},{"key":"1023_CR121","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.euo.2020.09.003","volume":"4","author":"C Nicolazzo","year":"2021","unstructured":"Nicolazzo, C., de Berardinis, E. & Gazzaniga, P. Liquid biopsy for predicting Bacillus Calmette-Gu\u00e9rin unresponsiveness in non-muscle-invasive bladder cancer. Eur. Urol. Oncol. 4, 124\u2013125 (2021).","journal-title":"Eur. Urol. Oncol."},{"key":"1023_CR122","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-023-01977-z","volume":"40","author":"D Jin","year":"2023","unstructured":"Jin, D. et al. In vivo detection of circulating tumor cells predicts high-risk features in patients with bladder cancer. Med. Oncol. 40, 113 (2023).","journal-title":"Med. Oncol."},{"key":"1023_CR123","doi-asserted-by":"publisher","first-page":"100416","DOI":"10.1016\/j.esmoop.2022.100416","volume":"7","author":"N Beije","year":"2022","unstructured":"Beije, N. et al. Circulating tumour cells to drive the use of neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer. ESMO Open\u00a07, 100416 (2022).","journal-title":"ESMO Open"},{"key":"1023_CR124","doi-asserted-by":"publisher","first-page":"5527","DOI":"10.1021\/acs.analchem.3c05749","volume":"96","author":"Z Wang","year":"2024","unstructured":"Wang, Z. et al. High-fidelity sensitive tracing circulating tumor cell telomerase activity. Anal. Chem. 96, 5527\u20135536 (2024).","journal-title":"Anal. Chem."},{"key":"1023_CR125","doi-asserted-by":"publisher","first-page":"115159","DOI":"10.1016\/j.bios.2023.115159","volume":"227","author":"J Wang","year":"2023","unstructured":"Wang, J. et al. A novel microfluidic system for enrichment of functional circulating tumor cells in cancer patient blood samples by combining cell size and invasiveness. Biosens. Bioelectron. 227, 115159 (2023).","journal-title":"Biosens. Bioelectron."},{"key":"1023_CR126","first-page":"502","volume":"15","author":"L Wang","year":"2023","unstructured":"Wang, L. & Ding, D. Correlation between mesenchymal circulating tumor cells and prognosis of urologic malignancies: a single-center retrospective analysis. Am. J. Transl. Res. 15, 502\u2013510 (2023).","journal-title":"Am. J. Transl. Res."},{"key":"1023_CR127","doi-asserted-by":"publisher","first-page":"101036","DOI":"10.1016\/j.neo.2024.101036","volume":"57","author":"Z Niu","year":"2024","unstructured":"Niu, Z. et al. Characterization of circulating tumor cells in patients with metastatic bladder cancer utilizing functionalized microfluidics. Neoplasia 57, 101036 (2024).","journal-title":"Neoplasia"},{"key":"1023_CR128","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-020-07684-6","volume":"20","author":"T-M Kim","year":"2020","unstructured":"Kim, T.-M. et al. Distinct mutation profiles between primary bladder cancer and circulating tumor cells warrant the use of circulating tumors cells as cellular resource for mutation follow-up. BMC Cancer 20, 1203 (2020).","journal-title":"BMC Cancer"},{"key":"1023_CR129","doi-asserted-by":"publisher","first-page":"S9","DOI":"10.1038\/d41586-020-00844-5","volume":"579","author":"C Alix-Panabi\u00e8res","year":"2020","unstructured":"Alix-Panabi\u00e8res, C. The future of liquid biopsy. Nature 579, S9 (2020).","journal-title":"Nature"},{"key":"1023_CR130","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1038\/s41416-023-02491-9","volume":"130","author":"Z Eslami-S","year":"2024","unstructured":"Eslami-S, Z. et al. Circulating tumour cells and PD-L1-positive small extracellular vesicles: the liquid biopsy combination for prognostic information in patients with metastatic non-small cell lung cancer. Br. J. Cancer 130, 63\u201372 (2024).","journal-title":"Br. J. Cancer"},{"key":"1023_CR131","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1126\/science.aar3247","volume":"359","author":"JD Cohen","year":"2018","unstructured":"Cohen, J. D. et al. Detection and localization of surgically resectable cancers with a multi-analyte blood test. Science 359, 926\u2013930 (2018).","journal-title":"Science"},{"key":"1023_CR132","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.3390\/cancers11111656","volume":"11","author":"E Buscail","year":"2019","unstructured":"Buscail, E. et al. High clinical value of liquid biopsy to detect circulating tumor cells and tumor exosomes in pancreatic ductal adenocarcinoma patients eligible for up-front surgery. Cancers 11, 1656 (2019).","journal-title":"Cancers"},{"key":"1023_CR133","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1002\/ijc.34964","volume":"155","author":"M Nesic","year":"2024","unstructured":"Nesic, M. et al. Beyond basics: key mutation selection features for successful tumor-informed ctDNA detection. Int. J. Cancer 155, 925\u2013933 (2024).","journal-title":"Int. J. Cancer"},{"key":"1023_CR134","first-page":"201","volume":"35","author":"AJ Bronkhorst","year":"2023","unstructured":"Bronkhorst, A. J. & Holdenrieder, S. The changing face of circulating tumor DNA (ctDNA) profiling: factors that shape the landscape of methodologies, technologies, and commercialization. Med. Genet. 35, 201\u2013235 (2023).","journal-title":"Med. Genet."},{"key":"1023_CR135","doi-asserted-by":"publisher","first-page":"11732","DOI":"10.3390\/ijms231911732","volume":"23","author":"R Carrasco","year":"2022","unstructured":"Carrasco, R. et al. Cell-free DNA as a prognostic biomarker for monitoring muscle-invasive bladder cancer. Int. J. Mol. Sci. 23, 11732 (2022).","journal-title":"Int. J. Mol. Sci."},{"key":"1023_CR136","doi-asserted-by":"publisher","first-page":"16578","DOI":"10.3390\/ijms242316578","volume":"24","author":"R Carrasco","year":"2023","unstructured":"Carrasco, R. et al. Tumor-agnostic circulating tumor DNA testing for monitoring muscle-invasive bladder cancer. Int. J. Mol. Sci. 24, 16578 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"1023_CR137","doi-asserted-by":"publisher","first-page":"10230","DOI":"10.3390\/ijms241210230","volume":"24","author":"A Chidharla","year":"2023","unstructured":"Chidharla, A. et al. Circulating tumor DNA as a minimal residual disease assessment and recurrence risk in patients undergoing curative-intent resection with or without adjuvant chemotherapy in colorectal cancer: a systematic review and meta-analysis. Int. J. Mol. Sci. 24, 10230 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"1023_CR138","doi-asserted-by":"publisher","first-page":"11521","DOI":"10.3390\/ijms231911521","volume":"23","author":"K Watanabe","year":"2022","unstructured":"Watanabe, K. et al. Tumor-informed approach improved ctDNA detection rate in resected pancreatic cancer. Int. J. Mol. Sci. 23, 11521 (2022).","journal-title":"Int. J. Mol. Sci."},{"key":"1023_CR139","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.202216505","volume":"15","author":"A Santonja","year":"2023","unstructured":"Santonja, A. et al. Comparison of tumor-informed and tumor-na\u00efve sequencing assays for ctDNA detection in breast cancer. EMBO Mol. Med. 15, e16505 (2023).","journal-title":"EMBO Mol. Med."},{"key":"1023_CR140","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1182\/blood-2015-03-631747","volume":"126","author":"DP Steensma","year":"2015","unstructured":"Steensma, D. P. et al. Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. Blood 126, 9\u201316 (2015).","journal-title":"Blood"},{"key":"1023_CR141","doi-asserted-by":"publisher","first-page":"4437","DOI":"10.1158\/1078-0432.CCR-18-0143","volume":"24","author":"Y Hu","year":"2018","unstructured":"Hu, Y. et al. False-positive plasma genotyping due to clonal hematopoiesis. Clin. Cancer Res. 24, 4437\u20134443 (2018).","journal-title":"Clin. Cancer Res."},{"key":"1023_CR142","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/978-1-0716-3291-8_11","volume":"2684","author":"I Nordentoft","year":"2023","unstructured":"Nordentoft, I., Birkenkamp-Demtr\u00f6der, K. & Dyrskj\u00f8t, L. NGS-based tumor-informed analysis of circulating tumor DNA. Methods Mol. Biol. 2684, 179\u2013197 (2023).","journal-title":"Methods Mol. Biol."},{"key":"1023_CR143","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.annonc.2023.12.007","volume":"35","author":"MA Gouda","year":"2024","unstructured":"Gouda, M. A. et al. Liquid biopsy response evaluation criteria in solid tumors (LB-RECIST). Ann. Oncol. 35, 267\u2013275 (2024).","journal-title":"Ann. Oncol."},{"key":"1023_CR144","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1373\/clinchem.2013.206359","volume":"59","author":"V Taly","year":"2013","unstructured":"Taly, V. et al. Multiplex picodroplet digital PCR to detect KRAS mutations in circulating DNA from the plasma of colorectal cancer patients. Clin. Chem. 59, 1722\u20131731 (2013).","journal-title":"Clin. Chem."},{"key":"1023_CR145","doi-asserted-by":"publisher","first-page":"102595","DOI":"10.1016\/j.ctrv.2023.102595","volume":"119","author":"R T\u00e9bar-Mart\u00ednez","year":"2023","unstructured":"T\u00e9bar-Mart\u00ednez, R. et al. Strategies for improving detection of circulating tumor DNA using next generation sequencing. Cancer Treat. Rev. 119, 102595 (2023).","journal-title":"Cancer Treat. Rev."},{"key":"1023_CR146","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.eururo.2017.09.011","volume":"73","author":"K Birkenkamp-Demtr\u00f6der","year":"2018","unstructured":"Birkenkamp-Demtr\u00f6der, K. et al. Monitoring treatment response and metastatic relapse in advanced bladder cancer by liquid biopsy analysis. Eur. Urol. 73, 535\u2013540 (2018).","journal-title":"Eur. Urol."},{"key":"1023_CR147","doi-asserted-by":"publisher","first-page":"14508","DOI":"10.1073\/pnas.1208715109","volume":"109","author":"MW Schmitt","year":"2012","unstructured":"Schmitt, M. W. et al. Detection of ultra-rare mutations by next-generation sequencing. Proc. Natl Acad. Sci. USA 109, 14508\u201314513 (2012).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1023_CR148","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1038\/s41587-021-00981-w","volume":"39","author":"DM Kurtz","year":"2021","unstructured":"Kurtz, D. M. et al. Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA. Nat. Biotechnol. 39, 1537\u20131547 (2021).","journal-title":"Nat. Biotechnol."},{"key":"1023_CR149","doi-asserted-by":"publisher","DOI":"10.1126\/science.adf2341","volume":"383","author":"C Martin-Alonso","year":"2024","unstructured":"Martin-Alonso, C. et al. Priming agents transiently reduce the clearance of cell-free DNA to improve liquid biopsies. Science 383, eadf2341 (2024).","journal-title":"Science"},{"key":"1023_CR150","doi-asserted-by":"publisher","first-page":"184945441667078","DOI":"10.1177\/1849454416670782","volume":"5","author":"A Gaziev","year":"2016","unstructured":"Gaziev, A., Abdullaev, S., Minkabirova, G. & Kamenskikh, K. X-rays and metformin cause increased urinary excretion of cell-free nuclear and mitochondrial DNA in aged rats. J. Circ. Biomark. 5, 1849454416670782 (2016).","journal-title":"J. Circ. Biomark."},{"key":"1023_CR151","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.euo.2019.08.004","volume":"4","author":"HJ Chalfin","year":"2021","unstructured":"Chalfin, H. J. et al. Circulating tumor cell and circulating tumor DNA assays reveal complementary information for patients with metastatic urothelial cancer. Eur. Urol. Oncol. 4, 310\u2013314 (2021).","journal-title":"Eur. Urol. Oncol."},{"key":"1023_CR152","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/s41571-023-00781-y","volume":"20","author":"R Lawrence","year":"2023","unstructured":"Lawrence, R., Watters, M., Davies, C. R., Pantel, K. & Lu, Y.-J. Circulating tumour cells for early detection of clinically relevant cancer. Nat. Rev. Clin. Oncol. 20, 487\u2013500 (2023).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1023_CR153","doi-asserted-by":"publisher","first-page":"5034","DOI":"10.1158\/1078-0432.CCR-24-1883","volume":"30","author":"AW Wyatt","year":"2024","unstructured":"Wyatt, A. W. et al. Plasma ctDNA as a treatment response biomarker in metastatic cancers: evaluation by the RECIST working group. Clin. Cancer Res. 30, 5034\u20135041 (2024).","journal-title":"Clin. Cancer Res."},{"key":"1023_CR154","unstructured":"Friends of Cancer Research. Framework for integrating change in ctDNA levels in advanced cancer clinical trials to support meta-analyses for intermediate endpoint validation (Friends of Cancer Research, 2024)."},{"key":"1023_CR155","unstructured":"US Food and Drug Administration. Use of circulating tumor deoxyribonucleic acid for early-stage solid tumor drug development; guidance for industry; availability (FDA, 2024)."}],"container-title":["Nature Reviews Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41585-025-01023-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41585-025-01023-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41585-025-01023-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T12:17:26Z","timestamp":1757161046000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41585-025-01023-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,15]]},"references-count":155,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["1023"],"URL":"https:\/\/doi.org\/10.1038\/s41585-025-01023-9","relation":{},"ISSN":["1759-4812","1759-4820"],"issn-type":[{"value":"1759-4812","type":"print"},{"value":"1759-4820","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,15]]},"assertion":[{"value":"14 March 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S.V. L. has an advisory\/consulting role for Cystotech. M.D.G. has received consultant fees from BioMotiv, Janssen, Merck, Dendreon, GlaxoSmithKline, Lilly, Astellas, Genentech, Bristol Myers Squibb, Novartis, Pfizer, EMD Serono, AstraZeneca, Seattle Genetics, Incyte, Aileron Therapeutics, Dracen, Inovio Pharmaceuticals and Numab; has received research funding from Janssen, Merck, Dendreon, Novartis, Bristol Myers Squibb, AstraZeneca and Genentech\/Roche; and owns stock in Rappta Therapeutics outside the submitted work; he also has a patent entitled Methods and compositions for treating cancer and related methods (Mount Sinai School of Medicine; 20120322792). T.P. has received honoraria from Astellas, AstraZeneca, Bristol Myers Squibb, Eisai, Exelixis, Gilead, Incyte, Ipsen, Johnson & Johnson, Mashup Media, Merck, MSD, Novartis, Pfizer, Roche and Seagen; has provided consulting or advisory services for Astellas, AstraZeneca, Bristol Myers Squibb, Eisai, Exelixis, Incyte, Ipsen, Johnson & Johnson, Mashup Media, Merck, MSD, Novartis, Pfizer, Roche and Seagen; has received research funding from Astellas, AstraZeneca, Bristol Myers Squibb, Eisai, Exelixis, Ipsen, Johnson & Johnson, Merck, MSD, Novartis, Pfizer, Roche and Seagen; and has received travel and accommodation support from AstraZeneca, Ipsen, MSD, Pfizer and Roche. J.B.J. is an advisory board member for Ferring, Roche, Cepheid, Urotech, Olympus, AMBU, Janssen and Cystotech; is a speaker for medac, Olympus, Intuitive Surgery and Photocure ASA; and has research collaborations with medac, Photocure ASA, Roche, Ferring, Olympus, Intuitive Surgery, Astellas, Cepheid, Nucleix, Urotech, Pfizer, AstraZeneca, MeqNordic, Laborie, VingMed, AMBU, and Cystotech. L.D. has sponsored research agreements with C2i Genomics, Veracyte, Natera, AstraZeneca, Photocure and Ferring; has an advisory\/consulting role for Ferring, MSD, UroGen and Cystotech; has received speaker honoraria from AstraZeneca, Pfizer and Roche; has received travel support from MSD; is a board member for BioXpedia. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}